2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Recruiting
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Gastrointestinal
1
Endocrine
1
Conditions
Pathologic Complete Response
1
Colorectal Neoplasms
1
Carcinoma, Neuroendocrine
1
Interventions
pembrolizumab
1265
Specimen Handling
926
Magnetic Resonance Spectroscopy
830
Carboplatin
823
Cyclophosphamide
800
Cisplatin
723
Nivolumab
669
Paclitaxel
627
Radiotherapy
611
Gemcitabine
573
Biopsy
557
Bevacizumab
478
Dexamethasone
438
fludarabine
407
Docetaxel
380
venetoclax
368
Oxaliplatin
364
Capecitabine
358
Fluorouracil
355
atezolizumab
350
durvalumab
332
Rituximab
330
Drug Therapy
326
Doxorubicin
316
Radiosurgery
315
Standard of Care
309
Blood Specimen Collection
308
Pemetrexed
305
Ipilimumab
299
Radiation
286
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
FOLFOXIRI protocol
×
1 year
×
Clear all
NCT02350530
2026-05-22
FORBES
Sun Yat-sen University
Phase 2
Completed
138 enrolled
NCT07472868
2026-03-16
MEND-IT II
Catharina Ziekenhuis Eindhoven
Phase 3
Not yet recruiting
394 enrolled
NCT04325425
2025-09-30
FOLFIRINEC
Centre Hospitalier Universitaire Dijon
Phase 2
Recruiting
218 enrolled